Sleep Apnea: Why Snoring May Be a Medical Condition — and Why Treatment Changes Everything

Sleep apnea is a condition in which breathing repeatedly stops and restarts during sleep, disrupting sleep architecture, causing intermittent oxygen desaturation, and producing a cascade of consequences — fatigue, cognitive impairment, and cardiovascular damage — that accumulate silently until they cannot be ignored. It affects an estimated 26 percent of adults aged 30 to 70, and approximately 80 percent of cases remain undiagnosed. This diagnostic gap is particularly consequential because untreated obstructive sleep apnea is an independent risk factor for hypertension, coronary artery disease, heart failure, atrial fibrillation, stroke, type 2 diabetes, and motor vehicle accidents. It is also highly treatable. Understanding what sleep apnea is, what symptoms suggest it, how it is diagnosed, and what treatment options exist — including the many alternatives for those who cannot tolerate CPAP — is the first step toward addressing a condition that has a profound effect on health and quality of life.

Types of Sleep Apnea

Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is by far the most common type, accounting for over 90 percent of sleep apnea cases. It occurs when the muscles of the upper airway relax during sleep, causing the tongue, soft palate, and pharyngeal walls to collapse and obstruct airflow. The obstruction reduces or completely stops airflow — a partial obstruction causing reduced airflow is a hypopnea, a complete cessation is an apnea — and the resulting oxygen desaturation and buildup of carbon dioxide trigger a brief arousal that reopens the airway. This cycle can occur hundreds of times per night, each arousal too brief to be remembered but sufficient to fragment deep and REM sleep. The person with OSA typically wakes feeling unrefreshed, not understanding why they are perpetually exhausted despite "sleeping" adequate hours.

Central Sleep Apnea

Central sleep apnea (CSA) results from a failure of the brain to send the appropriate respiratory drive signal to the breathing muscles during sleep, rather than from a mechanical airway obstruction. It is less common than OSA and more frequently associated with heart failure, opioid use, high-altitude exposure, and neurological conditions. Treatment differs from OSA management and typically involves adaptive servo-ventilation (ASV) or other ventilatory support modes.

Complex (Mixed) Sleep Apnea

Complex sleep apnea, also called treatment-emergent central sleep apnea, occurs when OSA patients develop central apneas after OSA is treated with CPAP — the central component was masked by the obstructive component and becomes apparent only after the obstruction is resolved. It requires adjustment of therapy, often to ASV, and frequently resolves over weeks to months of CPAP use.

The AHI and Severity Classification

The apnea-hypopnea index (AHI) is the primary metric used to diagnose and classify sleep apnea severity. It is defined as the number of apneas and hypopneas per hour of sleep. An AHI of 0 to 4 is normal; 5 to 14 is mild OSA; 15 to 29 is moderate OSA; 30 or above is severe OSA. However, AHI alone does not fully capture clinical severity. The degree of oxygen desaturation (with oxygen saturation falling below 90 percent for more than 5 percent of sleep time being clinically significant), the frequency of arousals, and the presence of daytime symptoms and cardiovascular consequences all inform the overall picture. A patient with an AHI of 12 who has intractable daytime sleepiness and uncontrolled hypertension is more clinically urgent than their mild classification might suggest.

Symptoms

Loud, disruptive snoring is the most recognizable symptom of OSA, but it is not universal — not everyone who snores has OSA, and not everyone with OSA is perceived as snoring loudly. Witnessed apneas — a bed partner observing the person stop breathing, gasp, or choke during sleep — are a highly specific symptom. Excessive daytime sleepiness (EDS), assessed with the Epworth Sleepiness Scale (a score of 10 or above suggesting significant sleepiness), is present in the majority of patients and is the symptom most consistently associated with quality of life impairment and accident risk. Morning headaches result from nocturnal hypercapnia and hypoxemia. Nocturia — waking to urinate multiple times per night — is driven by atrial natriuretic peptide release in response to the negative intrathoracic pressure changes of apneic events, and in many patients is the most bothersome symptom. Cognitive impairment — particularly difficulty with concentration, working memory, and executive function — is measurable on neuropsychological testing in untreated OSA and improves significantly with treatment. Mood changes, including depression and irritability, are common. Gastroesophageal reflux disease (GERD) is more prevalent in OSA patients because the negative intrathoracic pressures generated during airway obstruction promote gastric acid reflux. Erectile dysfunction in men with OSA improves with treatment.

Cardiovascular Consequences

The cardiovascular consequences of untreated OSA are among the most clinically significant reasons to diagnose and treat it. The repetitive cycles of hypoxemia, hypercapnia, arousal, and negative intrathoracic pressure activate sympathetic nervous system responses, raise blood pressure during apneic events, and over time produce sustained daytime hypertension that is often resistant to standard antihypertensive therapy. OSA is present in approximately 30 to 40 percent of hypertensive patients and in up to 70 percent of those with resistant hypertension. Atrial fibrillation is approximately 2 to 4 times more common in patients with severe OSA, and AF recurrence after cardioversion or ablation is substantially higher in untreated OSA. Coronary artery disease, heart failure, and stroke all have elevated incidence in OSA populations, with severity of AHI correlating with cardiovascular risk. Whether treating OSA reduces these cardiovascular outcomes remains the subject of ongoing research — CPAP has shown blood pressure lowering effects, but major cardiovascular outcome trials (SAVE, ISAACC) have not shown significant reductions in MACE, possibly because of suboptimal CPAP adherence in those trials.

Diagnosis: Home Sleep Test vs. Polysomnography

Polysomnography (PSG), conducted in a sleep laboratory overnight, remains the gold standard for sleep apnea diagnosis. It measures EEG (brain waves, sleep staging), EMG (muscle activity), EOG (eye movements), respiratory airflow, chest and abdominal effort, oxygen saturation, heart rate, body position, and limb movements simultaneously, providing a comprehensive characterization of sleep architecture and respiratory events. Home sleep apnea testing (HSAT) uses a simpler, portable device measuring airflow, respiratory effort, and oxygen saturation without sleep staging. HSAT is validated for diagnosing moderate to severe uncomplicated OSA and is significantly less expensive and more accessible. It tends to underestimate AHI because it divides events by total recording time rather than sleep time, and it misses central apneas. For most adults with a moderate-to-high pretest probability of OSA and without significant comorbidities, HSAT is an appropriate first diagnostic step. PSG is preferred when central sleep apnea, complex sleep apnea, or another sleep disorder is suspected, or when HSAT is inconclusive.

CPAP: The First-Line Treatment

Continuous positive airway pressure (CPAP) is the most effective treatment for OSA and is the standard first-line recommendation for moderate to severe OSA and for mild OSA with symptoms. CPAP delivers a continuous stream of pressurized air through a mask, acting as a pneumatic splint that holds the upper airway open throughout the night and prevents apneas. When used consistently, CPAP eliminates apneas and hypopneas, normalizes oxygen saturation, restores normal sleep architecture, and in most patients produces dramatic improvements in daytime sleepiness, cognitive function, mood, and cardiovascular parameters. Optimal CPAP pressure is determined during a titration study or by an auto-adjusting CPAP device (APAP), which varies the pressure breath by breath based on airway resistance detected.

Adherence is the central challenge. Approximately 30 to 50 percent of patients prescribed CPAP do not use it consistently (defined as 4+ hours per night on 70 percent of nights), most commonly due to mask discomfort, claustrophobia, nasal congestion, pressure intolerance, or air swallowing (aerophagia). Mask fitting is critical — a properly fitted mask for your face shape and breathing pattern (nasal pillow, nasal mask, full face mask) makes a major difference in comfort and tolerance. Heated humidification reduces nasal dryness and congestion. Desensitization techniques and graduated pressure introduction help claustrophobic patients. Consistent troubleshooting by a sleep specialist or respiratory therapist, rather than abandonment of the device, typically resolves most adherence barriers.

BiPAP

Bilevel positive airway pressure (BiPAP) delivers separate higher pressures on inhalation and lower pressures on exhalation, making exhalation against pressure easier and improving tolerance in patients who struggle with CPAP. BiPAP is first-line for central sleep apnea, complex sleep apnea, obesity hypoventilation syndrome, and patients with CPAP intolerance due to expiratory pressure difficulty.

Oral Appliances

Mandibular advancement devices (MADs) are custom-fitted dental appliances that hold the lower jaw forward during sleep, increasing the pharyngeal airspace and reducing upper airway collapse. They are less effective than CPAP for severe OSA — AHI reduction is typically less complete — but have significantly higher patient adherence because they are more comfortable. For mild to moderate OSA, MADs are a highly acceptable alternative and are recommended by the American Academy of Sleep Medicine as an alternative to CPAP when CPAP is not tolerated. A trained dental sleep medicine provider should fit the device; over-the-counter boil-and-bite devices are not equivalent.

Positional Therapy

Approximately 20 percent of OSA patients have position-dependent OSA — AHI in the supine (back-lying) position that is at least twice the AHI in the lateral position, with lateral AHI in the normal range. For these patients, positional therapy — preventing supine sleep through vibrating wearable devices, positional pillows, or sewn-in tennis ball techniques — can be highly effective and is appropriate as monotherapy or as an adjunct to other treatments.

Weight Loss

Weight loss is the most effective non-device intervention for OSA. A 10 percent weight reduction is associated with approximately 26 percent reduction in AHI. Significant weight loss through intensive lifestyle intervention or bariatric surgery can produce dramatic OSA improvement or resolution — studies of bariatric surgery in severely obese patients with OSA report AHI normalization in 40 to 80 percent of cases. However, weight loss alone is rarely sufficient for moderate to severe OSA, and CPAP should be maintained during weight loss efforts. GLP-1 receptor agonists, particularly tirzepatide (Zepbound, FDA-approved in 2024 specifically for OSA in obese patients), have shown in the SURMOUNT-OSA trial a 55 to 63 percent reduction in AHI with significant weight loss, representing a major advance in pharmacological management of OSA.

Surgical Options

Surgical treatments are reserved for patients who fail or cannot tolerate PAP therapy and oral appliances. Uvulopalatopharyngoplasty (UPPP), which removes soft tissue from the oropharynx, has variable efficacy and does not address all anatomical levels of obstruction. Hypoglossal nerve stimulation (Inspire), implanted in the chest and upper arm, delivers stimulation to the hypoglossal nerve timed to inspiration, protracting the tongue and opening the airway. It is FDA-approved for moderate to severe OSA in patients who fail CPAP and do not have complete concentric collapse at the soft palate on drug-induced sleep endoscopy. Inspire has excellent efficacy data and dramatically improved quality of life scores at 5-year follow-up. Maxillomandibular advancement surgery, which surgically moves both jaws forward to physically expand the pharyngeal space, has the highest surgical efficacy — AHI reduction of 80 to 90 percent in appropriate candidates — and is recommended for patients with specific skeletal anatomical contributors to OSA.

When to See a Doctor

If you snore loudly, wake unrefreshed, experience excessive daytime sleepiness, have been observed to stop breathing during sleep, or have hypertension that is difficult to control, you should be evaluated for sleep apnea. A simple home sleep test, guided by a physician, can confirm the diagnosis. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

Can thin people have sleep apnea?

Yes. While obesity is the strongest risk factor for OSA — with approximately 70 percent of OSA patients being overweight or obese — OSA occurs in non-obese individuals due to other anatomical factors including retrognathia (recessed jaw), macroglossia (large tongue), enlarged tonsils and adenoids, nasal polyps or septal deviation, and craniofacial structure. Asian populations have higher prevalence of OSA relative to BMI compared to Caucasian populations, likely due to skeletal factors affecting pharyngeal anatomy. Weight is not a prerequisite for OSA, and clinical suspicion should not be limited to obese patients.

Does sleep apnea go away?

OSA caused primarily by obesity can improve significantly or resolve with sufficient weight loss. OSA in children caused by enlarged tonsils and adenoids typically resolves after adenotonsillectomy. In adults without remediable anatomical causes, OSA is a chronic condition that requires ongoing treatment. Aging, nasal congestion, sedating medications, alcohol, and weight gain all worsen OSA; conversely, weight loss, alcohol avoidance, and positional adjustments can improve mild to moderate cases.

How does sleep apnea cause high blood pressure?

Each apnea event triggers a sympathetic nervous system surge as oxygen levels fall and the brain generates arousal. These surges acutely raise blood pressure during the event. With hundreds of events per night, the sympathetic nervous system's baseline tone is chronically elevated — spilling over into daytime as persistent sympathetic activation and elevated catecholamine levels. Over time, this remodels the vasculature and impairs baroreceptor function, producing sustained hypertension. CPAP treatment reduces sympathetic nervous system activity and lowers blood pressure, with effects most pronounced in patients with severe OSA and daytime hypertension.

Is it safe to drive if I have untreated sleep apnea?

Untreated moderate to severe OSA significantly increases the risk of motor vehicle accidents — estimates range from 2 to 7 times the risk compared to non-OSA individuals, driven by excessive daytime sleepiness and impaired vigilance. Many jurisdictions have regulations requiring drivers of commercial vehicles to be screened and treated for OSA. Effective CPAP treatment normalizes accident risk to that of the general population. Until OSA is diagnosed and effectively treated, individuals with significant daytime sleepiness should exercise caution and discuss driving safety with their physician.

Can alcohol worsen sleep apnea?

Yes, substantially. Alcohol relaxes upper airway muscles, worsens upper airway collapsibility, and suppresses the arousal response that normally reopens the airway during apnea — all of which increase the frequency and duration of apnea events. Studies show that even moderate alcohol consumption in the hours before sleep can double AHI in people with OSA and convert people with mild OSA into moderate or severe cases. Alcohol avoidance within 3 to 4 hours of bedtime is standard advice for OSA management, and completely avoidance in the evening is preferred for optimal treatment outcomes.